Intervacc (2E9) Stock Overview
Develops novel veterinary vaccines for animals in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2E9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Intervacc AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0076 |
| 52 Week High | SEK 0.11 |
| 52 Week Low | SEK 0.0067 |
| Beta | 0.37 |
| 1 Month Change | -92.56% |
| 3 Month Change | -76.32% |
| 1 Year Change | -83.00% |
| 3 Year Change | -99.26% |
| 5 Year Change | -99.90% |
| Change since IPO | -98.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2E9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -26.2% | -3.4% | -3.6% |
| 1Y | -83.0% | 6.7% | 0.7% |
Return vs Industry: 2E9 underperformed the German Biotechs industry which returned 5.4% over the past year.
Return vs Market: 2E9 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 2E9 volatility | |
|---|---|
| 2E9 Average Weekly Movement | 106.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 2E9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2E9's weekly volatility has increased from 74% to 106% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 15 | Carl-Johan Dalsgaard | intervacc.se |
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.
Intervacc AB (publ) Fundamentals Summary
| 2E9 fundamental statistics | |
|---|---|
| Market cap | €20.05m |
| Earnings (TTM) | -€7.57m |
| Revenue (TTM) | €1.88m |
Is 2E9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2E9 income statement (TTM) | |
|---|---|
| Revenue | SEK 20.09m |
| Cost of Revenue | SEK 31.57m |
| Gross Profit | -SEK 11.49m |
| Other Expenses | SEK 69.33m |
| Earnings | -SEK 80.81m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 14, 2026
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -57.18% |
| Net Profit Margin | -402.32% |
| Debt/Equity Ratio | 0.03% |
How did 2E9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/04 02:28 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intervacc AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Klas Palin | DNB Carnegie Commissioned Research |